Bayer Faces Two Court Decisions After $60 Billion Market Value Loss
BCS•Bayer AG has lost over $60 billion in market value since its Monsanto acquisition eight years ago, with two critical rulings in the next few weeks. The US Supreme Court is set to decide by early July on failed-warning claims while a €7.25 billion class-action fairness hearing follows shortly after.
1. Litigation Impact
Bayer’s $60 billion market value rout traces back to tens of thousands of Roundup cancer lawsuits tied to Monsanto’s herbicide labeling. The unresolved litigation has hampered the company’s financial planning, limiting debt reduction and earnings growth targets since the 2018 acquisition.
2. Supreme Court Case
The US Supreme Court will rule by early July on federal preemption of state failure-to-warn claims after reviewing a $1.25 million jury verdict linked to non-Hodgkin lymphoma. A favorable decision would eliminate key legal theories behind major multi-billion-euro awards in pending suits.
3. €7.25B Settlement Hearing
A fairness hearing will assess a €7.25 billion class-action deal covering current and future Roundup cancer claims. Approval of this settlement would resolve a significant portion of the litigation overhang and clarify long-term liability exposure.
4. Analyst Projections
One Jefferies forecast sets a €50 upside target if litigation clears, versus a €30 downside in a worst-case overhang. Other analysts assign roughly 70% odds to a favorable Supreme Court outcome, underscoring the high stakes for share price recovery.
